Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AHMADSHAH MIRKHEL

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1790729317
CMS profile
80670
Location
FAIRFAX, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$414.61

20 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $414.61 20

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AHMADSHAH MIRKHEL

NPI 1790729317 · CMS profile ID 80670

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

FAIRFAX, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790729317?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AHMADSHAH MIRKHEL, NPI 1790729317, CMS profile ID 80670. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790729317?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). AHMADSHAH MIRKHEL, NPI 1790729317, CMS profile ID 80670. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790729317?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
AHMADSHAH MIRKHEL, NPI 1790729317, CMS profile ID 80670, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1790729317?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

20 matching records · $414.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 20 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–20 of 20.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Fresenius USA Marketing, Inc. $18.4012/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051056641 CMS
GlaxoSmithKline, LLC. $29.3812/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003276667 CMS
Fresenius USA Marketing, Inc. $15.7911/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051056639 CMS
AstraZeneca Pharmaceuticals LP $21.1210/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016046971 CMS
Calliditas Therapeutics US Inc. $24.0010/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993491643 CMS
Novartis Pharmaceuticals Corporation $15.7810/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992946885 CMS
Travere Therapeutics, Inc. $8.1010/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059554583 CMS
Amgen Inc. $30.6110/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019777101 CMS
Aurinia Pharma U.S., Inc. $28.9709/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057743723 CMS
Amgen Inc. $13.4209/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020527631 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.4908/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055493623 CMS
Alnylam Pharmaceuticals Inc. $16.3608/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006197487 CMS
AKEBIA THERAPEUTICS INC $15.3906/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000054973 CMS
Vifor Pharma, Inc. $19.0206/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013134805 CMS
Horizon Therapeutics plc $28.5905/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987047433 CMS
AstraZeneca Pharmaceuticals LP $17.7105/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015377023 CMS
AKEBIA THERAPEUTICS INC $16.8004/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000054957 CMS
Travere Therapeutics, Inc. $20.6703/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059554585 CMS
GlaxoSmithKline, LLC. $22.0502/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003276671 CMS
Mallinckrodt Hospital Products Inc. $34.9601/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042862331 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $321.47 9
PY2020 $119.65 5
PY2021 $15.95 1
PY2022 $332.31 14
PY2023 $414.61 20
PY2024 $514.15 22
PY2025 $868.67 40

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $689,227.39 35
PY2024 Principal investigator $122,837.96 24
PY2023 Principal investigator $40,701.96 11
PY2022 Principal investigator $46,326.90 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,196.23 12/23/2024 Non-covered Recipient Entity
Nephrology Associates Of Northern Virginia Admin
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1107216412
Principal investigator 1 CSL Behring $484.30 12/05/2024 Non-covered Recipient Entity
Nephrology Associates of Northern Virginia
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142326238
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $290.14 11/26/2024 Non-covered Recipient Entity
Nephrology Associates Of Northern Virginia Admin
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1107216426
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,306.39 10/21/2024 Non-covered Recipient Entity
Nephrology Associates Of Northern Virginia Admin
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1085993942
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,054.55 10/10/2024 Non-covered Recipient Entity
Nephrology Associates Of Northern Virginia Admin
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1086008457
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,994.69 10/02/2024 Non-covered Recipient Entity
NEPHROLOGY ASSOCIATES OF NORTHERN VIRGINIA
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study) No dispute reported 06/30/2026 1089694855
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,238.20 09/26/2024 Non-covered Recipient Entity
Nephrology Associates Of Northern Virginia Admin
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1085993946
Principal investigator 1 CSL Behring $31.08 09/10/2024 Non-covered Recipient Entity
Nephrology Associates of Northern Virginia
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142326204
Principal investigator 1 Hoffmann-La Roche Limited $1,025.00 08/23/2024 Non-covered Recipient Entity
NEPHROLOGY ASSOCIATES OF NORTHERN VIRGINIA
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1133405314
Principal investigator 1 Hoffmann-La Roche Limited $54.00 08/23/2024 Non-covered Recipient Entity
NEPHROLOGY ASSOCIATES OF NORTHERN VIRGINIA
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1133405316
Principal investigator 1 Hoffmann-La Roche Limited $134.00 08/23/2024 Non-covered Recipient Entity
NEPHROLOGY ASSOCIATES OF NORTHERN VIRGINIA
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1133405318
Principal investigator 1 Hoffmann-La Roche Limited $96.00 08/23/2024 Non-covered Recipient Entity
NEPHROLOGY ASSOCIATES OF NORTHERN VIRGINIA
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1133405320
Principal investigator 1 Hoffmann-La Roche Limited $600.00 08/23/2024 Non-covered Recipient Entity
NEPHROLOGY ASSOCIATES OF NORTHERN VIRGINIA
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1133405322
Principal investigator 1 Hoffmann-La Roche Limited $8,772.00 08/23/2024 Non-covered Recipient Entity
NEPHROLOGY ASSOCIATES OF NORTHERN VIRGINIA
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1133405324
Principal investigator 1 Hoffmann-La Roche Limited $1,500.00 08/23/2024 Non-covered Recipient Entity
NEPHROLOGY ASSOCIATES OF NORTHERN VIRGINIA
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1133405326
Principal investigator 1 Hoffmann-La Roche Limited $1,800.00 08/23/2024 Non-covered Recipient Entity
NEPHROLOGY ASSOCIATES OF NORTHERN VIRGINIA
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1133405328
Principal investigator 1 CSL Behring $17.14 07/29/2024 Non-covered Recipient Entity
Nephrology Associates of Northern Virginia
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142326182
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $135.91 07/23/2024 Non-covered Recipient Entity
Nephrology Associates Of Northern Virginia Admin
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1085993944
Principal investigator 1 CSL Behring $1,955.43 07/02/2024 Non-covered Recipient Entity
Nephrology Associates of Northern Virginia
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142326150
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $171.63 07/01/2024 Non-covered Recipient Entity
Nephrology Associates Of Northern Virginia Admin
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1085993774
Principal investigator 1 Biogen, Inc. $693.30 04/12/2024 Non-covered Recipient Entity
Nephrology Associates Of Northern Virginia Inc
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) (EAGLE) No dispute reported 06/30/2026 1104837618
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,691.71 04/11/2024 Non-covered Recipient Entity
Nephrology Associates Of Northern Virginia Admin
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1086008461
Principal investigator 1 Novartis Pharmaceuticals Corporation $66,850.64 03/25/2024 Non-covered Recipient Entity
NEPHROLOGY ASSOCIATES OF NORTHER VIRGINIA
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function No dispute reported 06/30/2026 1089697717
Principal investigator 1 Biogen, Inc. $15,745.62 03/21/2024 Non-covered Recipient Entity
Nephrology Associates Of Northern Virginia Inc
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON) No dispute reported 06/30/2026 1104837294